Principles for adoptive T cell therapy of human viral diseases - PubMed (original) (raw)
Review
Principles for adoptive T cell therapy of human viral diseases
S R Riddell et al. Annu Rev Immunol. 1995.
Abstract
The development of successful adoptive immunotherapy for human virus infections is predicated on an understanding of the effector cells and mechanisms essential for providing the host with a protective response to acute infection and the requirements for long-term in vivo survival of transferred cells that will be necessary to provide memory responses to persistent and latent viral infections. In this review, we discuss the results of recent studies examining the effector mechanisms mediated by virus-specific alpha beta + T cells and the strategies viruses have evolved to evade recognition by such T cells and/or to interfere with the expression of T cell effector functions. The evasion strategies employed by individual viruses can render T cell subsets or T cells of particular specificities less effective in eliminating virally infected cells, and consequently they are less desirable choices for use in adoptive therapy. Insights derived from described studies of the pathogenesis and immunobiology of virus infections have resulted in the development of clinical adoptive immunotherapy studies for infections with CMV, EBV, and HIV. Although the results from such studies are preliminary, the principle that virus-specific T cells can be successfully transferred and can mediate therapeutic efficacy in humans has already been affirmed. The use of recently developed methods, such as retroviral-mediated gene transfer, to genetically modify antigen-specific T cell clones provides a novel approach to overcome limitations and improve on the safety and efficacy observed in these initial studies, suggesting that more widespread use of adoptive transfer of specific T cells as a therapeutic regimen should be feasible in the near future.
Similar articles
- Antigen-specific T cells for the treatment of infections after transplantation.
Einsele H. Einsele H. Hematol J. 2003;4(1):10-7. doi: 10.1038/sj.thj.6200213. Hematol J. 2003. PMID: 12692515 Review. - Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS, Mackinnon S. Peggs KS, et al. Hum Immunol. 2004 May;65(5):550-7. doi: 10.1016/j.humimm.2004.02.016. Hum Immunol. 2004. PMID: 15172456 Clinical Trial. - Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA, Reddehase MJ. Lemmermann NA, et al. Med Microbiol Immunol. 2016 Dec;205(6):549-561. doi: 10.1007/s00430-016-0471-0. Epub 2016 Aug 18. Med Microbiol Immunol. 2016. PMID: 27539576 Review. - Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios.
Quinn M, Turula H, Tandon M, Deslouches B, Moghbeli T, Snyder CM. Quinn M, et al. J Immunol. 2015 Feb 15;194(4):1726-1736. doi: 10.4049/jimmunol.1402757. Epub 2015 Jan 16. J Immunol. 2015. PMID: 25595792 Free PMC article.
Cited by
- Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.
Cornberg M, Sheridan BS, Saccoccio FM, Brehm MA, Selin LK. Cornberg M, et al. J Virol. 2007 Jan;81(2):934-44. doi: 10.1128/JVI.01280-06. Epub 2006 Nov 1. J Virol. 2007. PMID: 17079318 Free PMC article. - Therapeutic T cell engineering.
Sadelain M, Rivière I, Riddell S. Sadelain M, et al. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Nature. 2017. PMID: 28541315 Free PMC article. Review. - Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.
Wahid B, Ali A, Idrees M, Rafique S. Wahid B, et al. Cell Immunol. 2016 Dec;310:1-13. doi: 10.1016/j.cellimm.2016.08.001. Epub 2016 Aug 3. Cell Immunol. 2016. PMID: 27514252 Free PMC article. Review. - Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides.
Ghei M, Stroncek DF, Provenzano M. Ghei M, et al. J Transl Med. 2005 May 26;3:23. doi: 10.1186/1479-5876-3-23. J Transl Med. 2005. PMID: 15916715 Free PMC article. - Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.
Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Hertel L, et al. J Virol. 2003 Jul;77(13):7563-74. doi: 10.1128/jvi.77.13.7563-7574.2003. J Virol. 2003. PMID: 12805456 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical